c-KITmut is associated with resistance to the PARPi olaparib, but not to doxorubicin, in AML1-ETO–positiveAMLs. Clonogenic potential of Lin⁻CD34⁺ cells from AML patients harboring AML1-ETO (AE) or AML1-ETO + c-KITmut (AEK) and treated with the indicated concentrations of olaparib or doxorubicin. (A) Mean number of colonies from individual samples tested in triplicates. (B) Mean percentage ± standard deviation of colonies compared with untreated counterparts from the samples harboring the same mutations.